

李奧國際精準健康  
LEO INTERNATIONAL  
PRECISION HEALTH

# Building a global integrated AI-driven healthcare ecosystem

---

Börse Frankfurt (General Standard), Börse Düsseldorf  
Ticker Symbol: LEOW

May 11, 2026



# Disclaimer And Forward-Looking Statements

This presentation and the information contained herein are provided for information purposes only. It does not constitute, and shall not be construed as, a prospectus, an offer to sell, or a solicitation of an offer to buy or subscribe for any securities of the Company within the meaning of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG), the EU Market Abuse Regulation (MAR), the German Stock Corporation Act (Aktiengesetz – AktG), or any other applicable securities laws. Nothing in this presentation shall form the basis of, or be relied upon in connection with, any contract, commitment, or investment decision.

This presentation may include forward-looking statements concerning the present or future financial condition, results of operations, business performance, or strategic outlook of the Company, its subsidiaries, or assets contributed by asset owners in connection with an injection in kind. These statements are based on current expectations, assumptions, and information available from internal and external sources. Such forward-looking statements are subject to risks and uncertainties, many of which are beyond the Company's control, and actual results may differ materially. The Company and its management expressly disclaim any obligation to update or revise such statements and accept no liability for any loss or damage, whether direct or indirect, arising from the use of, reliance on, or distribution of this presentation or its contents.

Financial and operational information presented herein, whether relating to the Company, its subsidiaries, or the asset owners, may be unaudited, incomplete, or preliminary, and is provided for reference only. For audited financial information, please refer to the respective statutory financial statements.

Nothing in this presentation shall be construed as superseding or amending the rights and obligations of the Company's executive management board (Vorstand) or supervisory board (Aufsichtsrat) under German corporate law.

A portrait of Leo Wang, a man with dark hair, wearing a black shirt, standing with his arms crossed. The background features large, light blue letters spelling 'LEO' and 'WANG' and abstract green and blue wave patterns.

# LEO WANG

- **Founder and Chairman, with nearly 20 years of leadership experience in century-old international family enterprise**
- **Specialized in cross-industry brand innovation and collaboration**
- **Successfully transformed multiple multinational corporations**

---

## **Professional background:**

- Chairman and majority shareholder of Leo International Precision Health AG
- Founder of Leo International, largest Top-Tier Brand Agency Group in Asia
- General Manager of GOODYEAR Asia-Pacific/Taiwan/Hong Kong, U.S.-Listed
- General Manager of SWAROVSKI Taiwan, Hong Kong, and Macau
- Vice President of Operations, Swire Group Automotive Division

## **Academic background:**

- Exchange Student at Stanford Graduate School of Business, USA
- Executive Master in Marketing, City University of New York, USA
- Department of Economics, National Chengchi University

# Milestone

## 1926

Established extensive tea plantations in Linkou, New Taipei, supplying the northern Taiwan market, Established a red brick kiln factory.



## 1938

Mr. Wang Jinsheng founded Zhulinshan Temple in Linkou, New Taipei, and served as its manager for over 20 years.



## 1956

Established a trading company to conduct import and export of bulk raw materials in Taiwan.



## 1975

Progressively constructed small to medium-sized logistics warehouses on self-owned land in New Taipei and Taoyuan, providing cargo storage and logistics services.



## 1995

Established logistics headquarters to advance large-scale warehouse management, operating over 60 self-owned logistics warehouses throughout Taiwan.



## 1996

Ms. Hong, the mother, founded Fengyang Temple in Linkou, New Taipei, which has become a significant center of faith and fosters cross-strait cultural exchange.



## 2020

Establishment of a fully English-language foreign language kindergarten and experimental primary school



## 2021

Agency for the International Supermodel Competition



## 2022

Importation of yacht brands, acquisition of equestrian estates, asset management, dining and beverage, medical care, private aviation, travel, and resort brand agency and distribution  
Grand opening of the Taipei Dunbei Clubhouse



## 2023

Initiating IPO Advisory Acquisition Operations Initiated  
Established a Holding Company in the United States  
Established a Holding Company in Hong Kong  
Xiamen Yacht Club  
Singapore Clubhouse  
Taichung Clubhouse  
Taipei Xinyi Clubhouse  
Taipei Songshan Clubhouse  
Shanghai Clubhouse

## 2024

Cross-industry mergers and acquisitions in real estate, yachts, fashion and five companies as 100% subsidiaries  
Establishment of the Shanghai branch office  
Establishment of a joint venture company in Malaysia



## 2025

Successful RTO Listing on the Frankfurt Stock Exchange Main Board in Germany  
Breast Medical Center Grand Opening  
Commencement of Johor Bahru Yacht Marina Construction  
Ongoing Cross-Border M&A Activities



## 2026

Completion of AI technology and yacht marina business listing on the NASDAQ in the United States  
Ongoing Acquisition Operations To Become the Largest New Drug Development Company in Asia  
To Establish the Largest Chain Clinic System in Asia  
To Build a High-End Education System in Singapore  
Real Estate Operations in Kumamoto, Japan Have Commenced




# Top Ten Service Sectors



**Three strategic pillars: healthcare, finance, and education,** complemented with premium lifestyle and service brands

Healthcare protects life itself. Finance preserves and transfers value across time. Education shapes the capabilities, judgement, and leadership of future generations.

# A Diversified International Group Structure



# AI-Driven Precision Health Platform

李奧國際精準健康  
LEO INTERNATIONAL  
PRECISION HEALTH

## BUSINESS MODEL

Focus on acquiring and developing attractive opportunities, enhancing their value and selectively spinning them off, thereby generating shareholder value through **asset reconfiguration, revenue growth, licensing** and **royalties**.

## INVESTMENT CASE

Built on  
Innovation  
Synergy  
Scalability

- > Listed in the General Standard at the **Frankfurt Stock Exchange** as well as the **Düsseldorf Stock Exchange** (ticker symbol: LEOW)
- > Offering investors access to the expanding **Asian** and **global** healthcare and life sciences market.
- > Strategic focus on AI-driven precision health assets across **Healthcare Services, MedTech, HealthTech** and **Biotech**.

## CURRENT FLAGSHIP ASSETS

### Dr. Pain | 100% holding

Chain of clinics offering integrated pain management with AI-driven rehabilitation solutions.



### Pathomics Health | 67% holding


Advanced precision medicine and digital healthcare solutions for personalized prevention, diagnosis and treatment.




LEADERSHIP

# Experienced Team Bridging Science, Capital And Strategy

EXECUTIVE MANAGEMENT BOARD



SUPERVISORY BOARD



# Data-Driven Healthcare Ecosystem Projects Vast Opportunity

**MISSION**

From molecule to market – creating sustainable precision health impact



The global AI healthcare market is projected to reach **US\$ 868 billion** by 2030<sup>1</sup>


Healthcare is “below average” in its adoption of AI compared to other industries<sup>4</sup>

40% of new drug pipelines already AI-enabled<sup>2</sup>

30% of the world’s data volume generated by the healthcare industry<sup>3</sup>

Rising demand for predictive, preventive, personalized medicine

**AI ADOPTION IN HEALTHCARE 2025 vs. 2030<sup>1</sup>**



■ AI adoption 2025 ■ AI adoption 2030

<sup>1</sup> PwC (2025): [AI's US\\$ 868 billion healthcare revolution | Strategy&](#) | <sup>2</sup> Deloitte (2024): [us-advisory-generative-ai-regulation-in-life-sciences.pdf](#) | <sup>3</sup> RBC Capital Markets (2023): [https://www.rbccm.com/en/gib/healthcare/episode/the\\_healthcare\\_data\\_explosion](https://www.rbccm.com/en/gib/healthcare/episode/the_healthcare_data_explosion) | <sup>4</sup> World Economic Forum (2025): [Industries in the Intelligent Age White Paper Series | World Economic Forum](#)

# Structural Shifts Driving Growth



## Rising demand through aging populations

- > **By 2050**, 1 out of 6 will be 60 years or older<sup>1</sup>
- > **By 2035**, chronic disease incidents will increase by more than 40%<sup>1</sup>
- > **Healthcare systems under structural strain:** staff shortages, longer life expectancy, and greater chronic-care complexity



## Escalating healthcare costs

- > Global healthcare spending projected to surpass **USD 12 trillion by 2030**<sup>2</sup>
- > **Traditional models are unsustainable:** reactive, siloed, and resource-intensive



## Data explosion and fragmentation

- > **Data trapped across diagnostics, clinics, and pharma R&D** – Low interoperability limits value creation

### AI AS THE

## Catalyst for efficiency and scale



Predictive analytics can reduce hospital readmissions by **up to 20–30%**<sup>5</sup>

AI-driven drug design cuts preclinical timelines by **up to 50%**<sup>3</sup>

AI triage and scheduling tools in clinics improve resource utilization **by >25%**<sup>4</sup>

### OUTCOME



Lower costs



Faster innovation



Scalable personalized care

<sup>1</sup> UN (2024): World Population Prospects | <sup>2</sup> PwC (2025): [AI's US\\$ 868 billion healthcare revolution | Strategy&](#) | <sup>3</sup> BCC (2023): [Unlocking the potential of AI in Drug Discovery – 2023](#) | <sup>4</sup> Desai (2025): [AI in healthcare: Reducing processing costs and enhancing efficiency](#) | <sup>5</sup> NIH (2020): [Implementation of Artificial Intelligence-Based Clinical Decision Support to Reduce Hospital Readmissions at a Regional Hospital](#)

# Building Value Across The Full Precision Healthcare Continuum

## CRITERIA

Mostly AI-driven with focus on innovation, synergy and scalability

## Based on

- > Scientific validity
- > Regulatory readiness
- > Data integrity
- > Recurring revenue potential

## 4 complementary investment areas

that together cover the full continuum from discovery to patient care

1

### HEALTHCARE SERVICES


Personalized care such as clinics and nutraceuticals



3

### HEALTHTECH

Digital therapeutics and companions, software and predictive analytics



2

### MEDTECH

Medical devices and diagnostics such as next-gen imaging, digital pathology



4

### BIOTECH

Therapeutics and diagnostics such as liquid biopsy



## CURRENT PORTFOLIO OVERVIEW

# Current Portfolio Valued at ~ EUR 111 million

TAIWAN  
**amiko AI**



AI-driven software accelerating scientific discovery. Platform comprises Co-Scientist application for AI-assisted drug re-purposing and re-targeting.

54%



amiko AI

USA  
**Danner Lab**



Clinical cytopathology laboratory testing for precision healthcare. High-growth liquid biopsy service with AI-assisted imaging analysis services using proprietary CellBio™ technology and developing systems.

51%



HONG KONG  
**Dr PAIN** (Wankang Medical Group)



Pain rehabilitation with clinics across Taiwan, Hong Kong and China. High-margin pain therapy and rehabilitation services with evolving AI diagnostics capabilities.

100%



TAIWAN  
**UHO Wellness** (Immune Anima)



Nutraceuticals supporting standard of care cancer treatment. Core herbal products based on patented extraction process with 60%+  $\beta$ -glucans concentration.

67%



Uho 優活健康

SINGAPORE  
**Pathomics Health**



Advanced precision medicine and digital healthcare solutions for personalized prevention, diagnosis and treatment. B2B partnerships with life insurance firms, banks, hospitals and pharma.

52%



AUSTRALIA  
**Renhe Biotech**



Longevity and anti-aging health supplements including its NAD<sup>+</sup> product line. Patent-protected formulations manufactured with GMP standards and Therapeutic Goods Administration (TGA) sales registration in Australia.

51%



人和生物  
RENHE BIOTECH

# Turning Data, Science And Care Into Compounding Value

Synergies transform standalone assets into a **connected precision health ecosystem**



# Creating Shareholder Value by Adding Additional Nine Assets

Transaction scope  
**9 assets**

Acquisition of 9 companies across:

- > Preventative care clinics & beauty clinics (such as Funnel Group)
- > Healthcare platforms
- > Biotechnology & medical products businesses

Geographic focus:

- > Asia and Europe

Purchase price  
**EUR 400 – 500M**

Planned financing mix:

- > Bank financing
- > Listed corporate bond
- > Shareholder loans


EBITDA contribution  
**EUR 50 – 60M**

Planned financing mix:

- > Combining strong operational businesses
- > Clear integration and synergy strategy
- > Create a platform that is greater than the sum of its parts
- > Contribute long-term growth and value creation to LIPH's

Intended acquisitions reflect our approach to building a high-quality, scalable portfolio of healthcare assets

# Strategic Significance



Funnel Group would be the primary revenue engine, transforming the broader ecosystem from capability into commercial scale.

# Funnel Group – The Brands

The Funnel Group owns the following four cosmetic medical brands.

Since launching the medical slimming clinic “Dio Clinic” in November 2020, the group has built a comprehensive cosmetic medical group that ranks among the top five in the industry growing at the fastest pace in the industry’s history through in-house business development and M&A.

## DIO Clinic



No.1 medical slimming clinic chain in business for 4 years

Medical slimming

## e-clinic



Chain of cosmetic surgery clinics in business for 3 years

Cosmetic surgery

## FIN CLINIC



One of the few cosmetic surgery clinics focusing on men

Male cosmetic surgery


## Tokyo Ueno Clinic



One of the top male treatment clinic chains in Japan with a 30-year history

Urological surgery


# Funnel Group – Building Scale at Speed



The group currently operates **50** clinics throughout Japan focusing on cosmetic surgery and medical slimming



# Global LIPH Ecosystem



## FINANCIAL SNAPSHOT

# Balance Sheet as of Dec 31, 2025

In EUR thousand

Non-current assets	197,038
<i>Intangible assets</i>	195,692
<i>Property, plant and equipment</i>	416
<i>Right-of-use assets (IFRS 16)</i>	661
<i>Deferred tax assets</i>	270
Current financial assets	1,722
<b>Total assets</b>	<b>198,760</b>
Equity	172,868
Non-current liabilities	19,469
Current financial liabilities	6,424
<b>Total equity and liabilities</b>	<b>198,760</b>

The Group's financial position as of December 31, 2025, is primarily influenced by the initial contribution of the six portfolio companies as part of the capital increase through non-cash contributions in December 2025. Since the scope of consolidation was not established until the reporting date, the asset structure results primarily from the intangible assets identified and measured during the initial consolidation.

Intangible assets	In EUR thousand	Percentage of intangible assets
Goodwill	114,051	58%
Technologies	20,774	11%
Customer relationships	13,449	7%
Contractual rights	37,880	19%
Recipes	9,203	5%
Software	335	0%
<b>Total</b>	<b>195,692</b>	<b>100 %</b>

The Group's assets consist primarily of non-current assets, in particular goodwill and other intangible assets such as technologies and customer relationships, which were capitalized as part of the purchase price allocation for the acquired investments. There are no internally generated intangible assets.

### Acquisition of asset companies by way of capital increase against contributions in kind

Completion: Dec 16, 2025

Share issuance: 50,000 new no-par value bearer shares

Share capital post: EUR 550,000.00

## STOCK INFORMATION

# Shares

### Stock Information

**Ticker symbol** LEOW

**ISIN / WKN** DE0005490601 / 549060

**Segment** General Standard

**Share price** EUR 20.00  
(as of May 7, 2026)


**52-week high-low** EUR 36.00 – 1.00

**Shares issued** 550,000

**Market cap** ~EUR 11.99 million  
(as of May 7, 2026)

\* Includes members of the Executive Management Board as well as the Supervisory Board and associated shareholders

## Shareholder Structure



# Contact



[www.liphag.com](http://www.liphag.com)

## **Leo International Precision Health AG**

Am Klopferspitz 19  
82152 Planegg / Martinsried  
Germany

**Investor Relations &  
Public Relations Contact**

### **MC Services AG**

[LIPH@mc-services.eu](mailto:LIPH@mc-services.eu)

### **Leo International Precision Health AG**

[ir@liphag.com](mailto:ir@liphag.com)